Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include agents modulating the biological concentrations of trefoil factor family member 2 (TFF2) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include agents modulating the biological concentrations of trefoil factor family member 2 (TFF2) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include agents modulating the biological concentrations of trefoil factor family member 2 (TFF2) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: The invention relates to new peptides of the formula ##STR1## wherein R.sup.2 represents Ala or D-Ala,R.sup.11 represents Arg or D-Arg,R.sup.13 represents Val or Ile,R.sup.15 represents Gly, Leu, Phe or a valence bond,R.sup.27 represents Met or Nle,R.sup.28 represents Ser, D-Ser or Asn, andY represents OH or NH.sub.2,and to salts thereof. These compounds stimulate the release of growth hormone and can be used in the therapy as well as for veterinary or animal husbandry purposes.

Abstract: The invention relates to a process for obtaining ready-for-fertilization sexual products from sexually mature fish in a period independent of their natural spawning season, in which actual stage of ripening is determined by probing of sexual products [sperm or eggs], fish not yet ripe for ovulation are separated from ripe fish, compounds of hormonal effect are administered to fish, and after the ovulation sexual products are obtained from the fish or from their environment.In the process according to the invention a nonapeptide-C.sub.1-4 -alkyl-amide or a decapeptide amide of the general formula (I),Glp-His-Trp-Ser-Tyr-X.sub.1 -X.sub.2 -X.sub.3 -Pro-X.sub.4 (I)whereinX.sub.1 is a glycyl group or a D-isomer of any natural or synthetic amino acid group,X.sub.2 represents an L-amino acid group having 1 to 4 carbon atoms in the side chain, L-phenyl-alanyl or L-tryptophyl group,X.sub.3 represents an L-amino acid group having a C.sub.1-4 alkyl or C.sub.2-4 alkyl-amide side chain,X.sub.4 is a glycine-amide or a C.

Abstract: The invention relates to gonadoliberin derivatives of the general formula (I)Glp--His--Trp--Ser--Tyr--X.sub.1 --X.sub.2 --X.sub.3 --Pro--X.sub.4whereinX.sub.1 is a glycyl group or a D-isomer of any natural or synthetic amino acid group,X.sub.2 represents an L-amino acid group having 1 to 4 carbon atoms in the side chain, L-phenyl-alanyl or L-tryptophyl group,X.sub.3 represents an L-amino acid group having a C.sub.1-4 alkyl or C.sub.2-4 alkanoyl-amide side chain, andX.sub.4 is a glycine amide or a C.sub.1-4 alkyl amide group,with the proviso that if X.sub.1 stands for a group other than glycyl and X.sub.2 is a tryptophyl group then X.sub.3 may not be leucyl, and the addition salts formed with therapeutically useable acids and complexes thereof. Furthermore the invention relates to a process for preparing these compounds.The new gonadoliberin derivatives can be effectively used for the reproduction process of fish, birds and mammals.

Abstract: The invention relates to new gonadoliberin derivatives of the formula (I)Glp-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y, (I)whereinY represents a glycine-amide group or an -NH-alkyl group having 1 to 4 carbon atoms in the alkyl moiety,X stands for a D-thyroxyl, D-thyronyl or D-4-chlorophenylalanyl group,and acid addition salts and metal complexes thereof.The new nona- and decapeptide derivatives have an excellent luteinizing and folliculus stimulating hormone releasing activity, and they can therefore be used as active ingredients in pharmaceutical compositions for human or veterinary application.